Cargando…

Refining Adjuvant Therapy for Endometrial Cancer: New Standards and Perspectives

SIMPLE SUMMARY: In recent years, the adjuvant treatment of endometrial carcinoma has changed due to the integration of the molecular features in the clinical–pathological classification. The new ESGO/ESTRO/ESP guidelines (2021) proposed the evaluation of the adjuvant treatment of endometrial carcino...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giustozzi, Alessandra, Salutari, Vanda, Giudice, Elena, Musacchio, Lucia, Ricci, Caterina, Landolfo, Chiara, Perri, Maria Teresa, Scambia, Giovanni, Lorusso, Domenica
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8470828/ https://www.ncbi.nlm.nih.gov/pubmed/34571723 http://dx.doi.org/10.3390/biology10090845

Ejemplares similares

Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2022)

Therapeutic Potential of Tisotumab Vedotin in the Treatment of Recurrent or Metastatic Cervical Cancer: A Short Report on the Emerging Data
por: Agostinelli, Veronica, et al.
Publicado: (2023)

PARP Inhibitors Resistance: Mechanisms and Perspectives
por: Giudice, Elena, et al.
Publicado: (2022)

Dostarlimab: From preclinical investigation to drug approval and future directions
por: Cicala, Carlo Maria, et al.
Publicado: (2023)

Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?
por: Musacchio, L., et al.
Publicado: (2022)

Immunotherapy in gynecological cancers
por: Lorusso, Domenica, et al.
Publicado: (2021)

Adjuvant Treatment Recommendations in Early-Stage Endometrial Cancer: What Changes With the Introduction of The Integrated Molecular-Based Risk Assessment
por: Nero, Camilla, et al.
Publicado: (2021)

Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors
por: Nero, Camilla, et al.
Publicado: (2021)

Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early‐stage endometrial cancer: A propensity score–matched analysis
por: Nero, Camilla, et al.
Publicado: (2022)

Conservatively treated glassy cell carcinoma of the cervix
por: Ferrandina, Gabriella, et al.
Publicado: (2008)

Immunotherapy-Related Imaging Findings in Patients with Gynecological Malignancies: What Radiologists Need to Know
por: Russo, Luca, et al.
Publicado: (2021)

Recurrence in skeletal muscle from squamous cell carcinoma of the uterine cervix: a case report and review of the literature
por: Ferrandina, Gabriella, et al.
Publicado: (2006)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Clinical utility of trabectedin for the treatment of ovarian cancer: current evidence
por: Mascilini, Floriana, et al.
Publicado: (2014)

Refining adjuvant treatment in endometrial cancer based on molecular features: the RAINBO clinical trial program
Publicado: (2023)

Ovarian Cancer Metastasis to the Breast: A Case Report and Review of the Literature
por: Caruso, Giuseppe, et al.
Publicado: (2020)

Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey
por: Giannone, Gaia, et al.
Publicado: (2022)

Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
por: Arezzo, Francesca, et al.
Publicado: (2023)

Fiducial markers in adjuvant setting for a patient affected by endometrial cancer: a case report
por: Titone, Francesca, et al.
Publicado: (2023)

Integration of PARP-inhibitors in ovarian cancer therapy
por: Pietragalla, Antonella, et al.
Publicado: (2020)

Laparoendoscopic Single-Site Isobaric Hysterectomy in Endometrial Cancer
por: Fanfani, Francesco, et al.
Publicado: (2013)

Author's reply to: What is the prognostic importance of lymphovascular space invasion in the absence of lymph node metastasis for early-stage endometrial cancer?
por: Tortorella, Lucia, et al.
Publicado: (2021)

Medi-Cinema: A Pilot Study on Cinematherapy and Cancer as A New Psychological Approach on 30 Gynecological Oncological Patients
por: Chieffo, Daniela Pia Rosaria, et al.
Publicado: (2022)

Pegylated liposomal doxorubicin in the management of ovarian cancer
por: Ferrandina, Gabriella, et al.
Publicado: (2010)

Role of Immune Checkpoint Inhibitors in Cervical Cancer: From Preclinical to Clinical Data
por: Duranti, Simona, et al.
Publicado: (2021)

Adjuvant therapy for endometrial cancer
por: DeLeon, Maria C., et al.
Publicado: (2014)

Non-Coding RNAs as Prognostic Markers for Endometrial Cancer
por: Piergentili, Roberto, et al.
Publicado: (2021)

An Indirect Comparison of the Efficacy and Safety of Dostarlimab and Doxorubicin for the Treatment of Advanced and Recurrent Endometrial Cancer
por: Mathews, Cara, et al.
Publicado: (2022)

Advances in the Management of Recurrent Cervical Cancer: State of the Art and Future Perspectives
por: Giudice, Elena, et al.
Publicado: (2023)

A critical assessment on the role of sentinel node mapping in endometrial cancer
por: Bogani, Giorgio, et al.
Publicado: (2015)

Lymphadenectomy and adjuvant therapy in endometrial carcinoma: role of adjuvant chemotherapy
por: Otsuka, I, et al.
Publicado: (2002)

Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine
por: Nero, Camilla, et al.
Publicado: (2021)

Controversies in the Adjuvant Therapy of Endometrial Cancer
por: Hsiao, Sheng-Mou, et al.
Publicado: (2011)

How Immunotherapy Modified the Therapeutic Scenario of Endometrial Cancer: A Systematic Review
por: Maiorano, Brigida Anna, et al.
Publicado: (2022)

PARP Inhibitors in Endometrial Cancer: Current Status and Perspectives
por: Musacchio, Lucia, et al.
Publicado: (2020)

Oncologic Drugs Approval in Europe for Solid Tumors: Overview of the Last 6 Years
por: Falcone, Rosa, et al.
Publicado: (2022)

Long-term efficacy and safety of human papillomavirus vaccination
por: De Vincenzo, Rosa, et al.
Publicado: (2014)

Sentinel lymph node detection in endometrial cancer: does injection site make a difference?
por: Bogani, Giorgio, et al.
Publicado: (2016)

Prognostic refinement of NSMP high-risk endometrial cancers using oestrogen receptor immunohistochemistry
por: Vermij, Lisa, et al.
Publicado: (2023)

Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?
por: Mahdi, Haider, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1mp5702ppflk9g1q2qiikeig26